Anticytokine approaches in pulmonary fibrosis: bringing factors into focus
Open Access
- 1 March 1997
- Vol. 52 (3) , 294-296
- https://doi.org/10.1136/thx.52.3.294
Abstract
The prognosis of pulmonary fibrosis is poor and current therapies inadequate. Recent progress in understanding the mechanisms underlying the pathogenesis of this disease leads us to expect that inhibitors of cytokine and polypeptide growth factor will provide novel therapeutic agents. This paper outlines the role of cytokines in the pathogenesis of pulmonary fibrosis and concludes that there are compelling reasons to explore anticytokine therapeutic approaches. It also proposes criteria that will enable us to evaluate such agents in vivo and suggests approaches which might overcome the obstacles presented by control mechanisms which recruit a multiplicity of factors.Keywords
This publication has 10 references indexed in Scilit:
- Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.Proceedings of the National Academy of Sciences, 1996
- Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidneyNature Medicine, 1996
- Role of thrombin in pulmonary fibrosisThe Lancet, 1995
- Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis.Journal of Clinical Investigation, 1995
- Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro.American Journal of Respiratory Cell and Molecular Biology, 1994
- Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in miceEuropean Respiratory Journal, 1994
- Antisense S-Oligonucleotide against Tranforming Growth Factor- β1 Inhibits Proteoglycan Synthesis in Arterial WallJournal of Vascular Research, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney diseaseNature, 1992
- In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseasesClinical and Experimental Immunology, 1992